Abstract
Tamoxifen is used as an adjuvant therapy to reduce breast cancer recurrence among women with estrogen receptor positive tumors. Antidepressants are also commonly used in such women, to treat depression or to manage hot flushes, a frequent tamoxifen secondary effect. Some antidepressants could potentially inhibit cytochrome P450 2D6, required to activate tamoxifen, interfering with its action. Although there is not a clear cut directive on the subject, it is nowadays recommended to treat women with antidepressants with the lower cytochrome P450 2D6 inhibition potential to avoid a possible antagonism that may reduce tamoxifen s prevention of breast cancer recurrence at least in some patients with CYP2D6 genetic variation. The recommended antidepressants are desvenlafaxine, milnacipran, venlafaxin, escitalopram and citalopram.
Highlights
Antagonism of tamoxifen and antidepressants among women with breast cancer Tamoxifen is used as an adjuvant therapy to reduce breast cancer recurrence among women with estrogenreceptor positive tumors
Antidepressants are commonly used in such women, to treat depression or to manage hot flushes, a frequent tamoxifen secondary effect
Paroxetina* Fluoxetina* Bupropión epidemiológico retrospectivo en 1990 mujeres en tratamiento con TAM, no encontró correlación entre uso de inhibidores de la TAM y recurrencia de la enfermedad
Summary
Antagonism of tamoxifen and antidepressants among women with breast cancer Tamoxifen is used as an adjuvant therapy to reduce breast cancer recurrence among women with estrogenreceptor positive tumors. En una muestra de un estudio prospectivo fase III de mujeres postmenopáusicas con ca de mama RE (+) en tratamiento con 20 mg/d de TAM, que investigaba el impacto de la adición del andrógeno fluoximestron por un año, estudió el genotipo de 223 pacientes (alelos *4 y *6 de las CYP2D6). Estos estudios confirman los hallazgos de la relación entre el genotipo de la CYP2D6 y los resultados del tratamiento del TAM realizados en EEUU y Europa previamente descritos[15,16]. La frecuencia de CYP2D6 *4/*4 era significativamente más alta en las mujeres que desarrollaron cáncer en el subgrupo asignado a TAM (p = 0,015). Resumen de los principales estudios que evalúan el polimorfismo genético de los metabolizadores del TAM y recurrencia oncológica a largo plazo
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
